“although the human data on the sglt2 inhibitors is also remarkable and i think that's the sort of that's the theme here right is you have a great itp outcome and of course the human data are not for longevity but they're right again they suffer the the limitations of all human studies namely that they're being used in a subset of the population that might not be the subset of interest but you know the impact on kidney failure all-cause mortality heart failure is pretty impressive”
Main Takeaways:
- SGLT2 inhibitors have shown remarkable outcomes in human studies, though not specifically for longevity.
- These studies have limitations, such as being conducted on specific subsets of the population.
- Impacts observed include reductions in kidney failure, all-cause mortality, and heart failure.
Notes: Discussion on the effectiveness and limitations of human studies on SGLT2 inhibitors.
Tone: Cautious
Relevance: 4/5
“UK biobank people taking sglt2 Inhibitors seem to have lower all cause mortality so there may be a better case for a longevity effect”
Main Takeaways:
- SGLT2 inhibitors may reduce overall mortality according to UK Biobank data.
- Suggests potential longevity benefits from SGLT2 inhibitors.
Notes: Comparing the potential longevity effects of SGLT2 inhibitors and metformin.
Tone: Speculative
Relevance: 4/5
No comments yet.